Business Wire

Saladax Develops First-Ever Rapid Test for an Antipsychotic Drug Using a Single Drop of Blood to Aid Psychiatrists in the Treatment of Schizophrenia

5.9.2019 16:30:00 EEST | Business Wire | Press release

Share

Saladax Biomedical today announced that its MyCare Insite Clozapine Test is now CE marked for use on the MyCare Insite. The MyCare Insite Clozapine Test is the first and only rapid point-of-care test CE marked to aid mental health professionals in the treatment and monitoring of patients with schizophrenia.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190905005085/en/

The MyCare Insite Clozapine Test delivers accurate and precise clozapine blood levels comparable to laboratory results. Psychiatrists need immediate information to make informed decisions during a patient visit. The MyCare Insite Clozapine Test addresses this unmet medical need by providing answers in only six minutes. Clinicians, in consultation with their patients, can use these results to make real-time adjustments to better manage their patients.

"Mental health professionals have very few tools to aid in patient treatment; as a result, patients are suffering. The MyCare Insite Clozapine Test provides clinicians a first of its kind device. The test is evidence of how Saladax is once again setting new standards for innovation in the treatment and monitoring of patients," said Dr. Salvatore Salamone, CEO and Founder of Saladax Biomedical. "We are changing psychiatry with a single drop of blood.”

ABOUT PSYCHOSIS

Psychosis is a condition that affects the way your brain processes information. It causes you to lose touch with reality. Psychotic disorders, like schizophrenia, involve psychosis that usually affects you for the first time in the late teen years or early adulthood. Young people are especially at risk, but doctors don’t know why.

ABOUT THE MyCARE INSITE CLOZAPINE TEST

The MyCare Insite Clozapine Test is intended for the in vitro quantitative measurement of clozapine in human capillary finger blood using the MyCare Insite.

ABOUT SALADAX

Founded in 2004, Saladax Biomedical, Inc. is a privately held company headquartered as an anchor tenant at Ben Franklin TechVentures® located on Lehigh University’s campus in Bethlehem, PA.

Saladax develops rapid blood tests for point-of-care and for laboratory analysers for use in psychiatry and oncology. The Saladax MyCare Psychiatry line provides drug levels for greater insight into patient adherence and possible causes of treatment failures. These tests enable psychiatrists to more accurately assess adherence and better adjust medication dosing. Saladax believes that truly personalized medicine can only exist when the right drug is taken at the right dose. Our diagnostic reagent kits are distributed worldwide and are pending approval in the United States. Saladax is ISO 13485:2016 certified.

For more information, visit Saladax.com or MyCareTests.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Saladax Biomedical, Inc.
Salvatore Salamone, Ph.D., 610-419-6731
ssalamone@saladax.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ohmium Appoints Hydrogen Veteran as Chief Commercial Officer27.7.2026 11:05:00 EEST | Press release

Ohmium International Inc., a leading manufacturer of cutting-edge, high-efficiency, modular Proton Exchange Membrane (PEM) electrolyzers, today announced the appointment of Mark Griffin as Chief Commercial Officer (CCO). Griffin will serve as the executive lead of the Ohmium Sales and Marketing organization, driving revenue growth, customer acquisition, and the expansion of a global ecosystem of developers, industrial collaborators, and strategic partners. His appointment brings fresh momentum to Ohmium’s commercial stance as green hydrogen transitions from early adoption into mainstream industrial deployment. Griffin brings over two decades of experience in energy, including work in hydrogen and renewables. At ScottishPower, he spent five years leading hydrogen market development and business energy sales, spearheading two multi-megawatt green hydrogen projects totaling more than £220 million. Both projects were government-subsidized and structured around 15-year decarbonization offta

Uptime Institute Partners with the Governorate of Nineveh to Advance Iraq’s Digital Infrastructure at the U.S.-Iraq Business Summit27.7.2026 10:02:00 EEST | Press release

Uptime Institute today announced a landmark strategic partnership with the Governorate of Nineveh, signed at the U.S. Chamber of Commerce U.S.-Iraq Business Summit to accelerate the region’s digital transformation and advance Iraq’s national digital agenda. The agreement was signed on July 17, 2026, during the official U.S. visit of Iraqi Prime Minister Ali Al-Zaidi. Uptime Institute participated as part of the official delegation at a historic summit that yielded more than 50 agreements valued at over USD $60 billion, signaling a powerful new era of economic cooperation, investment, and technological innovation between the United States and Iraq. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260727139625/en/ Signing of landmark strategic partnership with Ali Al-Zaidi, Prime Minister of Iraq (right) and Uptime Institute's Mustapha Louni, Chief Business Officer (left). Under the Memorandum of Understanding (MOU), Uptime Inst

Objectway Expands Into Capital Markets With Its Project to Acquire French Specialist SLIB, Pushing Forward Its Pan-European Growth Strategy27.7.2026 09:45:00 EEST | Press release

Objectway, the pan-European wealthtech solution partner for banking, wealth and asset management firms, today announced that it has entered into exclusive negotiations with BNP Paribas and Natixis, granting them the right to transfer their entire stake in SLIB (Services Logiciels d'Intégration Boursière), a trusted partner specialised in the development of dedicated software solutions for the capital markets sector, to Objectway. The completion of the transaction remains subject to the satisfaction of customary conditions, including regulatory approvals and the finalisation of applicable information and consultation processes with the relevant employee representative bodies, and is expected to close by December 31, 2026. About SLIB SLIB (Services Logiciels d'Intégration Boursière) is a trusted technology partner to the capital markets industry. Founded in 1988 from the IT department of the Lyon Stock Exchange, SLIB has grown over more than 30 years into a specialised software provider

Ant Group Unveils Ling-3.0-Flash Delivering Top-Tier Performance at a Fraction of the Parameter Scale27.7.2026 09:00:00 EEST | Press release

Ant Group today announced the release of Ling-3.0-Flash, a next-generation native hybrid-reasoning foundational model engineered specifically for production-grade AI agent workflows. Designed to deliver rapid response capabilities, it serves as a high-speed execution node that offers a superior balance of intelligence density and cost-efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260726584441/en/ Ling-3.0-Flash delivers strong performance across multiple core benchmarks. Featuring 124B total parameters with only 5.1B active parameters per token, Ling-3.0-Flash achieves remarkable performance despite its streamlined footprint. It matches or surpasses industry-leading models with two to three times its parameter scale across core benchmarks, including foundational reasoning, instruction following, and long-context processing. Architectural Innovation for Efficiency Ling-3.0-Flash moves away from the traditional ap

SES Statement On FCC Upper C-band Auction Decision27.7.2026 08:30:00 EEST | Press release

SES, a leading space solutions company, issued the following statement following the U.S. Federal Communications Commission approval of the Upper C-band Report & Order that makes 160 megahertz of the Upper C-band available in the contiguous United States for flexible-use, next-generation terrestrial wireless services via a system of competitive bidding. The required auction of the Upper C-band will be completed no later than July 2027, with spectrum clearing deadlines in 2030 and 2031. Gross incentive payments of approximately $5.6 billion to SES are contingent on spectrum clearing within the transition deadlines. The Order also confirms reimbursement of reasonable and necessary Upper C-band transition costs as approved by the clearinghouse. SES CEO Adel Al-Saleh Commented: “We commend Chairman Carr and the FCC staff for their diligence, speed, and hard work. We remain fully committed to working cooperatively with the FCC and all stakeholders as the process progresses. We are pleased t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye